Hidradenitis Suppurativa (HS)NCT06960447
Nd:YAG vs Alexandrite Laser Treatment in Hidradenitis Suppurativa
A study testing Nd:YAG Laser and Alexandrite Laser in people with Hidradenitis Suppurativa (HS), run by Geisinger Clinic.
Trial summary
The purpose of this study is to evaluate whether Alexandrite laser treatment is non-inferior to Nd:YAG (neodymium-doped yttrium aluminum garnet) laser treatment of hidradenitis suppurativa (HS). Read more about this study
- Who is it for?
- Ages 12 to 75 years
- Conditions the study is for
- Hidradenitis Suppurativa (HS)
- What is being tested?
- Nd:YAG Laser and Alexandrite Laser
- Type of treatment
- Medical device
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 21 participants
- Where
- No sites listed yet
- Study dates
- Jul 2026to Jul 2027
- Phase
- Interventional
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 12 to 75 years
- All sexes
- No healthy volunteers
- Child, Adult, Older adult
Who may be able to join
- Geisinger male or female patients with a diagnosis of hidradenitis suppurativa (all stages of disease)
- 12-75 years of age
- Not on concurrent systemic therapy (e.g., antibiotics, biologic therapies)
- Must have not used systemic therapies within 2 weeks of enrollment in study
- Able and willing to provide consent
Who cannot join
- Patients who cannot tolerate laser therapy
- Patients who cannot wear protective eyewear
- Patients who are pregnant
Trial locations and contacts
No sites are listed yet. Contact the study team or a site near you to ask about taking part.
About this study
Official title: Comparative Efficacy of Nd:YAG and Alexandrite Laser Treatments in Hidradenitis Suppurativa: A Split-Person, Non-Inferiority Study
The purpose of this study is to evaluate whether Alexandrite laser treatment is non-inferior to Nd:YAG (neodymium-doped yttrium aluminum garnet) laser treatment of hidradenitis suppurativa (HS).
- Conditions
- Hidradenitis Suppurativa (HS)
- Being tested
- Nd:YAG Laser, Alexandrite Laser
- Medical subject headings
- Hidradenitis Suppurativa
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Nd:YAG LaserDevice
Nd:YAG laser applied to one side of the participant's body (e.g. left or right) according to randomization, every 4-6 weeks for 4 consecutive treatments.
Alexandrite LaserDevice
Alexandrite laser applied to the contralateral side of the participant's body (e.g. left or right) according to randomization, every 4-6 weeks for 4 consecutive treatments.
| Study group | Role | What they receive |
|---|---|---|
| Receiving treatment with both laser types | Experimental | Participants will receive split-body treatment, receiving Nd:YAG laser treatment to an affected anatomical site (axilla, inframammary region, or groin) and Alexandrite laser to the contralateral side. The treatment side will be randomized and maintained through the study. Receives: Device: Nd:YAG Laser; Device: Alexandrite Laser |
What is being measured
The primary outcome is the main question the study is designed to answer.
HiSCR50
Percentage of patients achieving a 50% reduction in their hidradenitis suppurativa clinical response (HiSCR) score.
Measured: 6 months
HiSQOL
The Hidradenitis Suppurativa Quality Of Life (HiSQOL) scale, a validated HS quality of life index and is comprised of a 17-item HS-specific HRQOL instrument with a 7-day recall period. Score ranges from 0 to 68, with higher scores indicating more severe impact
Measured: 6 months
Secondary outcomes (4)
Pain VAS score
Visual analogue score for pain ranging from 0-10 with higher scores indicating worse pain.
Measured: 6 months
Pruritus numeric rating scale
As measured by a numeric rating scale from 0-10 with higher scores indicating worse itching.
Measured: 6 months
Days free of disease in last 30 days
The number of days a patient has not had a flare of HS in the past 30 days.
Measured: 6 months
AN Count
Number of abscesses and nodules on exam
Measured: 6 months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted7 May 2025
- Study startJul 2026 (estimated)
- Primary completionJul 2027 (estimated)
- Study completionJul 2027 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Hidradenitis Suppurativa (HS)Studies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Not applicable
- Intervention model
- Single group
- Model description
- Split-person trial
- Masking
- None (open label)
- Enrolment
- 21 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Geisinger Clinic
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Mickey Horissian, Geisinger Clinic
- Investigators
- Mikael K Horissian, MD, Principal investigator, Geisinger Clinic
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06960447
- Sponsor's protocol ID
- 2024-0947
- Status last verified
- Apr 2026
- First submitted
- 28 Apr 2025
- Last updated
- 28 Apr 2026
- Results posted
- No
- FDA-regulated drug
- No
- FDA-regulated device
- Yes
- Individual data sharing
- No